The European Parliament could have helped to stimulate R&D into new drugs for rare diseases if it had not stuck so closely to the European Commission’s original proposals on orphan exclusivity periods, we argue in this piece for the Pink Sheet (paywall).
This article is a continuation from our previous analysis on the Commission’s proposals for orphan drugs.
For further information on this topic please contact Els Janssens, Olha Sviatenka, Magda Tovar and Julia Gillert.
